CYTOSORBENTS CORP's ticker is CTSO and the CUSIP is 23283X206. A total of 38 filers reported holding CYTOSORBENTS CORP in Q1 2017. The put-call ratio across all filers is 2.26 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2019 | $7,000 | -36.4% | 1,800 | -17.6% | 0.00% | – |
| Q3 2019 | $11,000 | +120.0% | 2,185 | +173.1% | 0.00% | – |
| Q2 2019 | $5,000 | -28.6% | 800 | 0.0% | 0.00% | – |
| Q1 2019 | $7,000 | -58.8% | 800 | -61.4% | 0.00% | – |
| Q4 2018 | $17,000 | -37.0% | 2,070 | 0.0% | 0.00% | – |
| Q3 2018 | $27,000 | +92.9% | 2,070 | 0.0% | 0.00% | – |
| Q2 2018 | $14,000 | 0.0% | 2,070 | 0.0% | 0.00% | – |
| Q1 2018 | $14,000 | +75.0% | 2,070 | +72.5% | 0.00% | – |
| Q4 2017 | $8,000 | -96.7% | 1,200 | -96.9% | 0.00% | -100.0% |
| Q3 2017 | $242,000 | +42.4% | 39,100 | -1.3% | 0.00% | +50.0% |
| Q2 2017 | $170,000 | -10.5% | 39,600 | -6.1% | 0.00% | 0.0% |
| Q1 2017 | $190,000 | -19.5% | 42,169 | -2.7% | 0.00% | -33.3% |
| Q4 2016 | $236,000 | -18.9% | 43,319 | -4.6% | 0.00% | -25.0% |
| Q3 2016 | $291,000 | +164.5% | 45,419 | +88.7% | 0.00% | +100.0% |
| Q2 2016 | $110,000 | +18.3% | 24,069 | +2.0% | 0.00% | 0.0% |
| Q1 2016 | $93,000 | -13.1% | 23,600 | +23.0% | 0.00% | 0.0% |
| Q4 2015 | $107,000 | – | 19,181 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| CM Management, LLC | 450,000 | $1,616 | 1.58% |
| Skylands Capital, LLC | 2,793,470 | $10,028,557 | 1.44% |
| Sargent Investment Group, LLC | 1,289,546 | $4,629,470 | 1.12% |
| JACOB ASSET MANAGEMENT OF NEW YORK LLC | 237,940 | $854,205 | 0.96% |
| Avenir Corp | 2,719,732 | $9,763,838 | 0.86% |
| Granahan Investment Management | 1,616,587 | $5,803,547 | 0.18% |
| Seelaus Asset Management LLC | 20,450 | $73 | 0.06% |
| Cowen Prime Advisors LLC | 42,301 | $151,861 | 0.05% |
| HighMark Wealth Management LLC | 10,000 | $35,900 | 0.03% |
| Key Client Fiduciary Advisors, LLC | 12,000 | $43,080 | 0.02% |